Reference Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Ref Type
PMID
Authors Stephen Mok, Colm Duffy, Reginald Du and James P. Allison
Title Blocking Colony Stimulating Factor 1 Receptor (CSF-1R) and Tropomyosin Receptor Kinase (Trk) improves antitumor efficacy of immunotherapy
Journal Vol Issue Date Pages Journal Short Title
Cancer Immunol Res
URL http://cancerimmunolres.aacrjournals.org/content/5/3_Supplement/PR01
Abstract Text Cancer Immunol Res 2017;5(3 Suppl):Abstract nr PR01

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Drug Name Trade Name Synonyms Drug Classes Drug Description
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
NTRK1 positive colon adenocarcinoma predicted - sensitive PLX7486 + unspecified CTLA4 antibody Preclinical - Cell line xenograft Actionable In a preclinical study, combination of PLX7486 and anti-CTLA4 immunotherapy resulted in enhanced anti-tumor effect compared to single therapy in animal models of Ntrk-positive colon adenocarcinoma (Cancer Immunol Res 2017;5(3 Suppl): Abstract nr PR01). detail...
NTRK1 positive colon adenocarcinoma predicted - sensitive PLX7486 + unspecified PD-1 antibody Preclinical - Cell line xenograft Actionable In a preclinical study, combination of PLX7486 and anti-PD-1 immunotherapy resulted in enhanced anti-tumor effect compared to single therapy in animal models of Ntrk-positive colon adenocarcinoma (Cancer Immunol Res 2017;5(3 Suppl): Abstract nr PR01). detail...
NTRK1 positive melanoma predicted - sensitive PLX7486 + unspecified PD-1 antibody Preclinical - Cell line xenograft Actionable In a preclinical study, combination of PLX7486 and anti-PD-1 immunotherapy resulted in enhanced anti-tumor effect compared to single therapy in animal models of Ntrk-positive melanoma (Cancer Immunol Res 2017;5(3 Suppl): Abstract nr PR01). detail...
NTRK1 positive melanoma predicted - sensitive PLX7486 + unspecified CTLA4 antibody Preclinical - Cell line xenograft Actionable In a preclinical study, combination of PLX7486 and anti-CTLA4 immunotherapy resulted in enhanced anti-tumor effect compared to single therapy in animal models of Ntrk-positive melanoma (Cancer Immunol Res 2017;5(3 Suppl): Abstract nr PR01). detail...